Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Ujiki, Michael B ^a   Ding, Xian Zhong ^a   Salabat, M Reza ^a   Bentrem, David J ^a   Golkar, Laleh ^a   Milam, Ben ^a   Talamonti, Mark S ^a   Bell Jr , Richard H ^a   Iwamura, Takeshi ^b   Adrian, Thomas E ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2; CELL CYCLE PROTEIN 25; CYCLIN A; CYCLIN B; DNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; TIME;

APIGENIN; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; CYCLIN B; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; HUMANS; MITOSIS; NUCLEIC ACID SYNTHESIS INHIBITORS; PHOSPHORYLATION;

EID: 33846653627     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-76     Document Type: Article

References (37)

1. Shah MA Kortmansky J Motwani I Drobnjak M Gonen M Yi S Weyerbacher A Cordon-Cardo C Lefkowitz R Brenner B O'Reilly E Saltz L Tong W Kelsen DP Schwartz GK A phase I clinical trial of sequential combination of irinotecan followed by flavopiridol Clin Cancer Res 2005, 11:3836-3845 10.1158/1078-0432.CCR-04-2651 15897584
2. Whitlock JA Krailo M Reid JM Ruben SL Ames MM Owen W Reaman G Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A Children's Oncology Group Study J Clin Oncol 2005, 23:9179-9186 10.1200/JCO.2004.01.0660 16361620
3. deVere White RW Hackman RM Soares SE Beckett LA Li Y Sun B Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer Urology 2004, 63:259-263. 10.1016/j.urology.2003.09.061 14972467
4. Kelland LR Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status Expert Opin Investig Drugs 2000, 9:2903-2911. 10.1517/13543784.9.12.2903 11093360
5. Fotsis T Pepper MS Aktas E Breit S Rasku S Adlercreutz H Wahala K Montesano R Schweigerer L Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis Cancer Res 1997, 57:2916-2921. 9230201
6. Li Y Ahmed F Ali S Philip PA Kucuk O Sarkar FH Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells Cancer Res 2005, 65:6934-6942. 10.1158/0008-5472.CAN-04-4604 16061678
7. Gupta S Afaq F Mukhtar H Involvement of nuclear factor-kappa B, bax and bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells Oncogene 2002, 21:3727-3738. 10.1038/ sj.onc.1205474 12032841
8. Lepley DM Li B Birt DF Pelling JC The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes Carcinogenesis 1996, 17:2367-2375. 8968050
9. Losiewicz MD Carlson BA Kaur G Sausville EA Worland PJ Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275 Biochem Biophys Res Commun 1994, 201:589-595. 10.1006/bbrc.1994.1742 8002990
10. Kobayashi T Nakata T Kuzumaki T Effect of flavonoids on cell cycle progression in prostate cancer cells Cancer Lett 2002, 176:17-23. 10.1016/S0304-3835(01)00738-8 11790449
11. Wang H The therapeutic potential of flavonoids Expert Opin Investig Drugs 2000, 9:2103-2119. 10.1517/13543784.9.9.2103 11060796
12. Birt D Hendrich S Wang W Dietary agents in cancer prevention: Flavonoids and isoflavonoids Pharmacol Ther 2001, 90:157-177. 10.1016/ S0163-7258(01)00137-1 11578656
13. Buchler P Reber HA Buchler MW Friess H Lavey RS Hines OJ Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression Cancer 2004, 100:201-210 10.1002/cncr.11873 14692041
14. Kim HP Mani I Iversen L Ziboh VA Effects of naturally-occurring flavonoids and bioflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs Prostaglandins Leukot Essent Fatty Acids 1998, 58:17-24. 10.1016/S0952-3278(98)90125-9 9482162
15. Yin F Giuliano AE Law RE Van Herle AJ Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-cdk regulators and ERK MAP kinase activation in breast carcinoma cells Anticancer Res 2001, 21:413-420. 11299771
16. Wang W Heideman L Chung CS Pelling JC Koehler KJ Birt DF Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines Mol Carcinog 2000, 28:102-110. 10.1002/ 1098-2744(200006)28:2<102::AID-MC6>3.0.CO;2-2 10900467
17. Caltagirone S Rossi C Poggi A Ranelletti FO Natali PG Brunetti M Aiello FB Piantelli M Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential Int J Cancer 2000 87 595-600 10.1002/ 1097-0215(20000815)87:4<595::AID-IJC21>3.0.CO;2-5 10918203
18. Yin F Giuliano AE Van Herle AJ Growth inhibitory effects of flavonoids in human thyroid cancer cell lines Thyroid 1999, 9:369-376. 10319943
19. Takahashi T Kobori M Shinmoto H Tsushida T Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells Biosci Biotechnol Biochem 1998, 62:2199-2204. 10.1271/bbb.62.2199 9972240
20. Kuo ML Yang NC Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes Biochem Biophys Res Commun 1995, 212:767-775. 10.1006/bbrc.1995.2035 7626110
21. Van Dross R Xue Y Knudson A Pelling JC The chemopreventive bioflavonoid apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma cell lines J Nutr 2003:SUppl 133 3800-3804.
22. Wei H Tye L Bresnick E Birt DF Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice Cancer Res 1990, 50:499-502. 2105157
23. Chaumontet C Droumaguet C Bex V Heberden C Gaillard-Sanchez I Martel P Flavonoids (apigenin, tangeretin) counteract tumor promoter-induced inhibition of intercellular communication of rat liver epithelial cells Cancer Lett 1997, 114:207-210. 10.1016/S0304-3835(97)04664-8 9103293
24. Norbury C Nurse P Animal cell cycles and their control Annu Rev Biochem 1992, 61:441-470. 10.1146/annurev.bi.61.070192.002301 1497317
25. Johnson DG Walker CL Cyclins and cell cycle checkpoints Annu Rev Parmacol Toxicol 1999, 39:295-312. 10.1146/annurev.pharmtox.39.1.295
26. Sampath D Plunkett W Design of new anticancer therapies targeting cell cycle checkpoint pathways Curr Opin Oncol 2001, 13:484-490. 10.1097/ 00001622-200111000-00011 11673689
27. Mailand N Podtelejnikov AV Groth A Mann M Bartek J Lukas J Regulation of G2/M events by cdc25A through phosphorylation-dependent modulation of its stability EMBO J 2002, 21:5911-5920. 131064 12411508 10.1093/emboj/ cdf567
28. Furuno N Den Elzen N Pines J Human cyclin A is required for mitosis until mid prophase J Cell Biol 1999, 147:95-306. 10.1083/jcb.147.2.295
29. Pagano M Pepperkok R Verde F Angorge W Draetta G Cyclin A is required at two points in the human cell cycle EMBO J 1992, 11:961-971. 556537 1312467
30. Lepley DM Pelling JC Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin Mol Carcinog 1997, 19:74-82. 10.1002/ (SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L 9210954
31. Lindenmeyer F Li H Menashi S Soria C Lu H Apigenin acts on the tumor cell invasion process and regulates protease production Nutr Cancer 2001, 39:139-147. 10.1207/S15327914nc391_19 11588896
32. O'Prey J Brown J Fleming J Harrison PR Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells Biochem Pharmacol 2003, 66:2075-2088. 10.1016/j.bcp.2003.07.007 14609732
33. Casagrande F Darbon JM Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: Regulation of cyclin-dependent kinases CDK2 and CDK1 Biochem Pharmacol 2001, 61:1205-1215. 10.1016/S0006-2952(01)00583-4 11322924
34. McVean M Weinberg WC Pelling JC A p21WAF1-independent pathway for inhibitory phosphorylation of cyclin-dependent kinase p34cdc2 and concomitant G2/M arrest by the chemopreventive flavonoid apigenin Mol Carcinog 2002, 33:36-43. 10.1002/mc.10016 11807956
35. Trochon V Blot E Cymbalista F Engelman C Tang R Thomaidis A Vasse M Soria J Lu H Soria C Apigenin inhibits endothelial-cell proliferation in G2/M phase whereas it stimulates smooth-muscle cells by inhibiting p21 and p27 expression Int J Cancer 2000, 85:691-696. 10.1002/ (SICI)1097-0215(20000301)85:5<691::AID-IJC15>3.0.CO;2-Q 10699950
36. Gupta S Afaq F Mukhtar H Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells Biochem Res Commun 2001, 287:914-920. 10.1006/ bbrc.2001.5672
37. Taylor WR Stark GR Regulation of the G2/M transition by p53 Oncogene 2001, 20:1803-1815. 10.1038/sj.onc.1204252 11313928